A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 27, 2011

Primary Completion Date

February 3, 2012

Study Completion Date

February 3, 2012

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

ASP1941

Oral

DRUG

Placebo

Oral

Trial Locations (1)

Neuss

All Listed Sponsors

lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT01611363 - A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin | Biotech Hunter | Biotech Hunter